Literature DB >> 28930025

Unrecognized Subclinical Infection with Tickborne Encephalitis Virus, Japan.

Kentaro Yoshii, Reiji Kojima, Hiroshi Nishiura.   

Abstract

During early 2017, we conducted a seroepidemiologic investigation for tickborne encephalitis virus among 291 Japan Self-Defense Forces members in Hokkaido. Two (0.7%) tested positive. Neither had clinically apparent symptoms after removing ticks.

Entities:  

Keywords:  Japan; Japanese encephalitis virus; Subclinical infection; flaviviruses; neutralizing antibody; seroepidemiologic study; tick-borne encephalitis virus; ticks; vector-borne infections; viruses; zoonoses

Mesh:

Substances:

Year:  2017        PMID: 28930025      PMCID: PMC5621547          DOI: 10.3201/eid2310.170918

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


Tickborne encephalitis virus (TBEV; genus Flavivirus, family Flaviviridae) persists in ticks and wild animals, including wild rodents and shika deer (,). Geographically, the virus is widely spread across Eurasia and annually causes ≈10,000 clinically apparent cases in humans (). In Japan, tickborne encephalitis is notifiable. Two confirmed cases, both in Hokkaido in the northernmost prefecture, have been reported. The first confirmed case was serologically diagnosed in 1993 (); the second case was confirmed in 2016. During the 20-year gap between cases, serologic and virologic surveys of wild animals (,) clarified that TBEV has been maintained in animal populations, especially in wild rodents in Hokkaido. Given the continued ecologic findings of virus activity in animals, it is plausible that humans have acquired TBEV infection, especially persons frequently exposed to ticks, including Japan Self-Defense Forces (JSDF) members of the Northern Army. We report the result from a pilot seroepidemiologic study of JSDF members conducted to determine the presence of unrecognized infections and to crudely measure the frequency. We recruited 291 JSDF members who belong to the Northern Army and who received tick bites during ground activities (). During their general health screening in February and March 2017, participants were asked to provide an additional 2 mL of serum for laboratory testing and to answer a questionnaire about the frequency of tick bites. We conducted neutralizing antibody testing using the virus isolated from Hokkaido in 1993 (). We determined a serum sample to be TBEV positive if >50% plaque reduction compared with healthy human control serum was observed. We defined neutralizing titer as the reciprocal of the highest dilution of serum. To differentiate TBEV infection from Japanese encephalitis virus (JEV) infection, which occurs in southwestern Japan, we also conducted neutralization testing for JEV on all TBEV-positive samples. The Medical Ethics Committees at the Graduate School of Medicine, Hokkaido University and JSDF Sapporo Hospital approved this study. The research team explained to participants that the enrollment was voluntary and gave participants the right to withdraw. We obtained written informed consent from participants, and no names were assigned to serum samples or questionnaires. Participants ranged in age from 35 to 54 years (mean 43.3 years). A total of 288 (99.0%) of the 291 participants were men. Ninety-two (31.6%; 95% CI 26.5%–37.1%) participants appeared to have been bitten by ticks >1 time during the previous 10 years; participants were bitten a mean of 1.4 (SD ± 1.1) times. Two (0.7%; 95% CI 0.0%–1.7%) persons appeared to have been infected with TBEV; both were negative for JEV, the only other flavivirus in Japan. The TBEV-positive participants were men 42 and 48 years of age who had been bitten 3 and 1 times, respectively, within the previous 10 years (Table). Neither man complained of symptoms of TBEV infection, such as high-grade fever, headache, nausea, or paralysis after tick removal; however, the 48-year-old participant noted right knee joint pain, inguinal lymph node swelling, and low-grade fever, which he attributed to the remaining body part of a tick.
Table

Neutralizing antibody titers against TBEV and JEV among members of the Japan Self-Defense Forces screened in early 2017*

Patient age, yReceived tick bite in previous 10 yAntibody titer†
TBEV
JEV
423 times80<20
481 time40<20

*JEV, Japanese encephalitis virus; TBEV, tickborne encephalitis virus.
†Neutralizing titer was defined as the reciprocal of the highest dilution of serum.

*JEV, Japanese encephalitis virus; TBEV, tickborne encephalitis virus.
†Neutralizing titer was defined as the reciprocal of the highest dilution of serum. These 2 unrecognized subclinical TBEV infections were serologically diagnosed, demonstrating that humans who are particularly at risk for tick bites are partly asymptomatically infected with TBEV in Hokkaido. Because flaviviruses are known to serologically cross-react with other close flaviviruses (), we tested serum against JEV, the only other endemic flavivirus in Japan, and successfully excluded its possibility. The antibody titer was lower than that in persons with clinically apparent cases (e.g., >1,600), perhaps because the virus replication was limited among subclinical cases or antibody had decayed since infection. Our findings echo similar cross-sectional survey results among persons recently bitten by ticks in Xinjiang and Inner Mongolia, China (). Although the estimated frequency in Japan was as low as 0.7%, this figure should not be regarded as small, considering that >30,000 persons serve in the Northern Army. In addition, frequently bitten persons include not only JSDF members but also dairy farmers, foresters, and hikers. Seroepidemiologic surveys with greater sample size and broader scope of study participants are needed to identify persons at high risk for infection and determine the pros and cons of specific countermeasures, including vaccination (). Such surveys also are needed to measure the virulence of TBEV of the so-called Far-Eastern subtype because the detection of subclinical or mild cases may lead to an overall decrease in its case-fatality risk, which is perceived as high ().
  9 in total

Review 1.  Tick-borne encephalitis in China: A review of epidemiology and vaccines.

Authors:  Yi Xing; Heinz-Josef Schmitt; Adriano Arguedas; Junfeng Yang
Journal:  Vaccine       Date:  2017-01-30       Impact factor: 3.641

2.  Correlation between ELISA, hemagglutination inhibition, and neutralization tests after vaccination against tick-borne encephalitis.

Authors:  H Holzmann; M Kundi; K Stiasny; J Clement; P McKenna; C Kunz; F X Heinz
Journal:  J Med Virol       Date:  1996-01       Impact factor: 2.327

3.  A case of tick-borne encephalitis in Japan and isolation of the the virus.

Authors:  I Takashima; K Morita; M Chiba; D Hayasaka; T Sato; C Takezawa; A Igarashi; H Kariwa; K Yoshimatsu; J Arikawa; N Hashimoto
Journal:  J Clin Microbiol       Date:  1997-08       Impact factor: 5.948

Review 4.  Tick-borne encephalitis 2010: epidemiology, risk areas, and virus strains in Europe and Asia-an overview.

Authors:  Jochen Süss
Journal:  Ticks Tick Borne Dis       Date:  2010-12-17       Impact factor: 3.744

5.  Epizootiological study of tick-borne encephalitis virus infection in Japan.

Authors:  Kentaro Yoshii; Keita Mottate; Yuki Omori-Urabe; Yumiko Chiba; Takahiro Seto; Takahiro Sanada; Junko Maeda; Mayumi Obara; Shuji Ando; Naoto Ito; Makoto Sugiyama; Hiroshi Sato; Hiroshi Fukushima; Hiroaki Kariwa; Ikuo Takashima
Journal:  J Vet Med Sci       Date:  2010-11-02       Impact factor: 1.267

6.  Genetic and biological characterization of tick-borne encephalitis virus isolated from wild rodents in southern Hokkaido, Japan in 2008.

Authors:  Yoshii Kentaro; Shoko Yamazaki; Keita Mottate; Noriyo Nagata; Takahiro Seto; Takashiro Sanada; Mizuki Sakai; Hiroaki Kariwa; Ikuo Takashima
Journal:  Vector Borne Zoonotic Dis       Date:  2013-04-16       Impact factor: 2.133

Review 7.  Tick-borne encephalitis virus - a review of an emerging zoonosis.

Authors:  K L Mansfield; N Johnson; L P Phipps; J R Stephenson; A R Fooks; T Solomon
Journal:  J Gen Virol       Date:  2009-05-06       Impact factor: 3.891

Review 8.  Tick-borne encephalitis.

Authors:  Lars Lindquist; Olli Vapalahti
Journal:  Lancet       Date:  2008-05-31       Impact factor: 79.321

9.  Characterization of neutralizing antibodies to Far Eastern of tick-borne encephalitis virus subtype and the antibody avidity for four tick-borne encephalitis vaccines in human.

Authors:  Galina N Leonova; Elena V Pavlenko
Journal:  Vaccine       Date:  2009-03-03       Impact factor: 3.641

  9 in total
  2 in total

1.  Serologic Evidence of Tick-Borne Encephalitis Virus Infection in a Patient with Suspected Lyme Disease in Japan.

Authors:  Kentaro Yoshii; Kozue Sato; Mariko Ishizuka; Shintaro Kobayashi; Hiroaki Kariwa; Hiroki Kawabata
Journal:  Am J Trop Med Hyg       Date:  2018-05-24       Impact factor: 2.345

2.  Estimating the Force of Infection with Helicobacter pylori in Japan.

Authors:  Taishi Kayano; Ki-Deok Lee; Hiroshi Nishiura
Journal:  Can J Infect Dis Med Microbiol       Date:  2019-01-30       Impact factor: 2.471

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.